ClearPoint Neuro Earnings Reports

ClearPoint Neuro delivered an 11% year-over-year revenue increase in Q1 2025, with record revenue of $8.5 million. Growth was led by significant gains in consumables and single-use navigation and therapy products, offset slightly by lower capital equipment sales.

ClearPoint Neuro reported a 14% increase in revenue for the fourth quarter of 2024, reaching $7.8 million. The company's full-year revenue grew by 31% to $31.4 million. They also reduced operational cash burn by 35% for the year and fully repaid a $10 million convertible note, leaving them with no outstanding debt. The company activated six new global centers in the fourth quarter, with a total of 25 in 2024.

ClearPoint Neuro reported a record revenue quarter with $8.1 million, a 41% year-over-year increase. The company's growth was fueled by new product introductions, adoption of the PRISM laser therapy system, and expansion of pre-clinical capabilities. Operational cash burn was reduced, and the company reaffirmed its full year 2024 revenue outlook of between $30.0 and $33.0 million.

ClearPoint Neuro reported a strong second quarter with record revenue of $7.9 million, a 32% year-over-year increase. Product revenue more than doubled, and the company saw significant growth in Biologics and Drug Delivery revenue and Neurosurgery Navigation revenue. The company also raised its full-year revenue guidance to between $30.0 and $33.0 million.

ClearPoint Neuro reported a strong first quarter in 2024, achieving record revenue of $7.6 million, a 41% year-over-year increase. The company saw significant growth in biologics and drug delivery revenue, as well as capital equipment sales, and reduced its operational cash burn.

ClearPoint Neuro reported a record revenue of $6.8 million for Q4 2023, a 32% increase year-over-year, and a reduced quarterly cash burn to $1.2 million. The company reaffirmed its 2024 revenue guidance to be between $28.0 million and $32.0 million.

ClearPoint Neuro reported a 12% increase in revenue for Q3 2023, driven by strong growth in biologics and drug delivery. The company also significantly reduced its operational cash burn and made progress on strategic initiatives.

ClearPoint Neuro reported a record quarterly revenue of $6.0 million, a 14% year-over-year increase, driven primarily by the growth in biologics and drug delivery services.

ClearPoint Neuro reported a revenue of $5.4 million for Q1 2023, an 8% increase compared to Q1 2022. The company reaffirmed its full-year 2023 revenue outlook of $25.0 to $27.0 million.

ClearPoint Neuro reported a 21% year-over-year increase in fourth quarter revenue, reaching $5.2 million. The company's full-year revenue grew by 26% to $20.6 million. They also reiterated their 2023 revenue forecast of between $25 and $27 million.

ClearPoint Neuro reported a strong third quarter with a 13% increase in revenue year-over-year, reaching $5.1 million. The company reaffirmed its full-year 2022 revenue outlook of $21.0 to $22.0 million and highlighted the European Commission's marketing authorization for Upstaza, a gene therapy treatment to be administered with ClearPoint's SmartFlow® Neuro Cannula.

ClearPoint Neuro reported a record quarterly revenue of $5.2 million, a 52% year-over-year increase. The biologics and drug delivery business became the largest segment with product and service revenue growing at more than 70%. The company reaffirmed its full year 2022 revenue outlook of between $21.0 and $22.0 million.

ClearPoint Neuro reported a strong first quarter in 2022, achieving record revenue in both Functional Neurosurgery Navigation and Biologics and Drug Delivery, resulting in a total revenue of $5.0 million, a 25% increase year-over-year. The company is increasing its range of expected revenue for 2022 to between $21.0 and $22.0 million.

ClearPoint Neuro reported a 15% increase in total revenue for Q4 2021, reaching $4.3 million compared to $3.7 million in Q4 2020. The company's cash and cash equivalents totaled $54.1 million.

ClearPoint Neuro announced its financial performance for the third fiscal quarter ended September 30, 2021.

ClearPoint Neuro reported a successful second quarter of 2021, highlighted by record case volume, demonstrating a return to pre-pandemic levels ahead of schedule. The company is also working with more than 30 partners in the drug delivery space and expects to add additional partners in the second half of 2021.

ClearPoint Neuro reported a strong first quarter with record revenue of $4.0 million, a 29% increase year-over-year. The company saw growth across all its business segments and ended the quarter with nearly $65.0 million in cash, bolstered by a successful public equity offering in February.

ClearPoint Neuro reported a revenue of $3.7 million for the fourth quarter of 2020, compared to $3.2 million for the same period in 2019. The company is optimistic about returning to pre-COVID procedure volume in the second half of 2021.

ClearPoint Neuro reported record revenue of $3.5 million for Q3 2020, a 20% increase compared to Q3 2019. The increase was driven primarily by a 162% increase in biologics and drug delivery revenues.

ClearPoint Neuro reported a decrease in total revenue by 5% compared to the same quarter last year, reaching $2.5 million. The decrease was primarily driven by the COVID-19 pandemic, which led to the postponement or cancellation of elective surgical procedures. However, the biologics and drug delivery business increased by 183%.

ClearPoint Neuro reported a 26% year-over-year increase in total revenues, reaching $3.1 million for the first quarter of 2020. However, the company experienced a significant impact from the COVID-19 pandemic, which led to the postponement of elective surgeries and a subsequent reduction in case volume. The company withdrew its case and revenue forecast for 2020.

ClearPoint Neuro reported a 53% increase in revenue for the full year 2019, with fourth-quarter revenue growing by 41%. The company saw growth across all four segments of its business and secured over $25 million in financing from strategic partners.